Coronavirus (COVID-19) Clinical Trials

MUSC is meeting the challenge of the novel coronavirus, COVID-19, through research aimed at discovering vaccines, new treatments, and ways to prevent or reduce the spread of the virus.

Pediatric COVID Vaccine Study

Complete a brief form to be contacted with more information about Pediatric COVID-19 Vaccine Research Opportunities.

Vaccine Trial

Cheryl Bath swabs Kelly Warren's nose to test for any reactions during her first visit to the COVID-19 vaccine trial run by MUSC and AstraZeneca. 

A vaccine trial volunteer writes about her experience participating in COVID-19 research.

Part 1: Vaccine Trial
Part 2: Appointment Day
Part 3: After the Shot
Part 4: Follow-up Appointment
Part 5: Second Shot
Part 6: Looking Ahead

COVID-19 Study Opportunities

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Recruitment Contact:
Elizabeth Szwast

Multi-center, Randomized, Case-controlled, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 therapy) in COVID-19 Subjects with Acute Kidney Injury Receiving Renal Replacement Therapy 

Recruitment Contact:
Marcie Pregulman

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19

Recruitment Contact:
Linda Walker

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19

Recruitment Contact:
Abigail Grady

COVID-19: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19

Recruitment Contact:
Abigail Grady

The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina

Recruitment Contact:
Judith Shary

Expanded Access to Convalescent Plasma for the Treatment of Pediatric Patients with COVID-19 

Thank you for your interest is plasma donation.

For information regarding plasma donation or to schedule an appointment to make a donation, please contact:

The Blood Connection (854-429-1700) or the American Red Cross(843-764-2323) by phone or by visiting their websites to learn more.

If you have been tested for COVID-19 and need your test results for your plasma donation appointment, you can access these results by logging into MUSC Health MyChart and accessing the “Health” tab and selecting “Test Results”

If you do not yet have a MyChart account, visit MUSC Health MyChart and click the blue “Create Your Account” button to create one (this can take up to 48 hours).

If do not want to access this information through MyChart or if you cannot locate your COVID-19 lab results in MyChart, you may request your results from the MUSC medical records department at 843-792-3881.

If you were tested for COVID-19 at a non-MUSC facility, please contact your physician or the records department at that facility.

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease (COVID-19)

Recruitment Contact:
Ebony Dawkins Mikell

COVID-19 Vaccine Studies

Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)

Recruitment Contact:
Megan Santilli

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

Recruitment Contact:
Pediatric Research team

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Status: Closed for Enrollment

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Status: Closed for Enrollment

Update: For AstraZeneca Patients with an EUA Approved Vaccine (Pfizer, Moderna) Appointment email the study team for instructions.

A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants

Status: Closed for Enrollment

SCTR / MUSC COVID-19 Biorepository

The Medical University of South Carolina (MUSC) is developing a COVID-19 biorepository which will contain blood, urine, and other bodily fluids along with relevant medical information from individuals evaluated, exposed to, or treated for COVID-19.

Recruitment is currently paused.

Healthcare Worker Exposure Response & Outcomes (HERO) Registry

MUSC is participating in the HERO Registry, a large, national clinical research community. Healthcare workers across America may join the registry to share clinical and life experiences to understand the perspectives and problems they face on the COVID-19 pandemic front lines.

Visit the HERO Registry website to learn more and join the registry.

MUSC Contact for questions regarding the HERO Registry:

Elizabeth Szwast

Additional Opportunities

SC logo

View a full list of active COVID-19 research opportunities, including study details and contact information at (Keyword search for coronavirus and COVID-19.)